3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER_GOV
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
NET
1
Endocrine
1
Conditions
Breast Neoplasms
23
Ovarian Neoplasms
18
Neoplasm Metastasis
12
Triple Negative Breast Neoplasms
9
Prostatic Neoplasms
9
Pancreatic Neoplasms
8
Neoplasms
8
Fallopian Tube Neoplasms
6
Squamous Cell Carcinoma of Head and Neck
4
Advanced Solid Tumors
4
Small Cell Lung Carcinoma
3
Recurrence
3
Head and Neck Neoplasms
3
Endometrial Neoplasms
3
Carcinoma, Squamous Cell
3
Solid Tumors
2
Sarcoma
2
Neuroendocrine Tumors
2
Lymphoma
2
Lung Neoplasms
2
Hodgkin Disease
2
Fanconi Anemia, Complementation Group D1
2
Carcinoma, Non-Small-Cell Lung
2
Advanced Solid Tumours
2
Advanced Solid Tumor
2
Advanced Cancer
2
Triple Negative Metastatic Breast Cancer
1
Thymoma
1
Thrombocytosis
1
Solid Tumor
1
Interventions
pembrolizumab
2
Cyclophosphamide
2
Celecoxib
2
olaparib
1
isophosphamide mustard
1
fludarabine
1
entinostat
1
bosutinib
1
anetumab ravtansine
1
Pemetrexed
1
Imatinib Mesylate
1
Gemcitabine
1
FANG vaccine
1
Cisplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Thymoma
×
olaparib
×
Clear all
NCT04375267
2026-04-14
LuPARP
Vastra Gotaland Region
Phase 1
Completed
18 enrolled